Roche Says It Will Launch Mircera
The FDA is expected to approve Mircera sometime in the middle of the year. If Roche then begins selling the drug, it could be subject to triple damages if it loses the suit against Amgen.
Nonetheless, Roche said it was confident of winning the case.
“Mircera…differs from existing...
To view the full article, register now.